publication venue for
- Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis. 25:397-409. 2024
- Systematic methodological review of health state values in glaucoma cost-utility analyses 2024
- Canada population norms for the EQ-5D-5L. 25:147-155. 2024
- Identifying factors associated with high use of acute care in Canada: a population-based retrospective study. 24:1505-1515. 2023
- Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. 22:723-733. 2021
- Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials. 21:717-728. 2020
- An 8-step framework for implementing time-driven activity-based costing in healthcare studies. 20:1133-1145. 2019
- Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. 18:967-977. 2017
- The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation. 17:979-990. 2016
- Health state utilities associated with attributes of treatments for hepatitis C. 16:1005-1018. 2015
- Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection?. 16:847-855. 2015
- Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best–worst scaling?. 15:281-288. 2014
- The impact of tobacco prices on smoking onset in Vietnam: duration analyses of retrospective data. 15:19-39. 2014
- Internal validation of models with several interventions. 14:901-909. 2013
- The cost-effectiveness of cash versus lottery incentives for a web-based, stated-preference community survey. 13:789-799. 2012
- Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study. 11:27-34. 2010
- Procedures and methods of benefit assessments for medicines in Germany: give the child a name. 10:237-238. 2009